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Background
In 2010, the FDA approved the use of extended-release
injectable naltrexone (Vivitrol©) for the treatment of
opioid dependence. Preliminary evidence from prior stu-
dies indicates that monthly injections of Vivitrol are
effective in treating opioid dependence after initial
detoxification. This longitudinal exploratory study mea-
sures demographics, medication adherence, sobriety
(urinalysis), utilization of care, and mental and emo-
tional states in patients who were treated for opioid
dependence with injectable naltrexone at an addictions
stabilization center.
Materials and methods
Participants involved in the VPP completed surveys
upon intake and before and after each monthly injec-
tion. Participants included patients who completed
detoxification and initiated injectable naltrexone treat-
ment (n = 71) compared to patients who dropped out of
the protocol against medical advice (AMA) (n = 73).
Data were analyzed using STATA (v12); Pearson’s chi-
square and Fisher’s exact tests for categorical variables;
and t-tests for continuous variables.
Results
Quantitative results indicate that more patients who
completed detoxification and received at least the first
injection had previous medication-assisted treatments
(MAT) program experience compared to patients who
left AMA (72% vs. 58%). Participants with prior knowl-
edge of injectable naltrexone were more likely to
complete detoxification and receive an injection com-
pared to treatment-naïve patients (61.19% vs. 45.07%).
Patients were more likely to engage in group sessions
with each injection (first injection 33%; second 82%)
Between the first and second injections, the percentage
of participants receiving emergency care decreased
(35.29% vs. 27.91%).
Conclusions
The findings from this study indicate that previous
knowledge of extended-release naltrexone and prior
MAT experience may influence the initiation and com-
mitment to use of this MAT. Patients who remained in
the program engaged more actively in group sessions,
had higher senses of control over their drug use, and
had lower rates of utilization for urgent care.
Authors’ details
1Department of Public Health & Preventive Medicine, Oregon Health &
Science University, Portland, OR, 97239-3098, USA. 2Hooper Detoxification
and Stabilization Center, Portland, OR, 97232, USA.
Published: 20 February 2015
doi:10.1186/1940-0640-10-S1-A54
Cite this article as: Rieckmann et al.: The Vivitrol pilot program (VPP):
initial quantitative findings from an extended-release naltrexone study.
Addiction Science & Clinical Practice 2015 10(Suppl 1):A54.
* Correspondence: rieckman@ohsu.edu
1Department of Public Health & Preventive Medicine, Oregon Health &
Science University, Portland, OR, 97239-3098, USA
Full list of author information is available at the end of the article
Rieckmann et al. Addiction Science & Clinical Practice 2015, 10(Suppl 1):A54
http://www.ascpjournal.org/content/10/S1/A54
© 2015 Rieckmann et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
